Moderna Inc
MRNA.OQ- Latest Trade
- trading higher137.91USD
- Change
- 0
- % Change
0.00%
- Day Range
- 132.34 - 141.60
- 52-Week Range
- 119.02 - 497.00
As of May 16 2022. Values delayed up to 15 minutes
- Previous Close
- 137.91
- Open
- 132.69
- Volume
- 2,065,789.00
- 3 Month Average Trading Volume
- 155.54
- Shares Out (Mil)
- 397.76
- Market Capitalization
- 54,855.02
- Forward P/E
- 4.97
- Dividend Yield
- -99,999.99
Key Statistics
2.5 mean rating - 20 analysts
- P/E Excl. Extra Items (TTM)
- 4.06
- Price To Sales (TTM)
- 2.43
- Price To Book (Quarterly)
- 3.23
- Price To Cash Flow (Per Share TTM)
- 3.67
- Total Debt/Total Equity (Quarterly)
- 4.72
- Long Term Debt/Equity (Quarterly)
- 3.78
- Return On Investment (TTM)
- 129.40
- Return On Equity (TTM)
- 72.64
2021 (millions USD)
About Moderna Inc
Company Information
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.
Address
200 Technology SqCambridge, MA
02139-3578
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Noubar B. Afeyan
- Non-Executive Independent Chairman of the Board, Co-Founder
- Stephen Hoge
- President
- Stephane Bancel
- Chief Executive Officer, Director
- David Meline
- Chief Financial Officer
- Tracey Franklin
- Chief Human Resources Officer
- Juan Andres
- Chief Technical Operations and Quality Officer
- Paul Burton
- Chief Medical Officer
- Kate Cronin
- Chief Brand Officer
- Marcello Damiani
- Chief Digital and Operational Excellence Officer
- Shannon Thyme Klinger
- Corporate Secretary, Chief Legal Officer
- Stephen Berenson
- Independent Director
- Sandra J. Horning
- Independent Director
- Robert S. Langer
- Independent Director
- Elizabeth G. Nabel
- Independent Director
- Francois Nader
- Independent Director
- Paul Sagan
- Independent Director
- Elizabeth E. Tallett
- Independent Director
Latest News
- Asian MarketsKohl's, Peloton, EV stocks
U.S. stock indexes plunged on Monday, with the S&P 500 on course to confirm a correction as the prospect of a Russian attack on Ukraine posed as a double whammy for investors already worried about aggressive monetary policy tightening by the Federal Reserve.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,807.40 | -- |
| Copper | 755.00 | 0.27%Positive |
| Brent Crude Oil | 110.01 | 1.38%Negative |
| CBOT Soybeans | 1,663.25 | 1.02%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,023.89 | 2.39%Positive |
| Euro STOXX 50 | 3,703.42 | -- |
| FTSE 100 | 7,418.15 | 2.55%Positive |
| Nikkei 225 | 26,547.05 | 0.45%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes